Diagnostic Utility of PAX5 in Hodgkin and Non-Hodgkin Lymphoma: A Study from Northern India

Johri, Nidhi; Patne, Shashikant C. U.; Tewari, Mallika; Kumar, Mohan

doi:10.7860/jcdr/2016/21476.8352

Cited by 8 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B cell lymphoma, status post rituximab lacks CD 20 expression, however strong expression of PAX-5 makes it an ideal immunohistochemical marker for establishing the diagnosis in such cases (Chu et al, 2006) In one of the study of Dong et al PAX-5 expression was identified in 97% cases of B-lymphoproliferative disorders (Hodgkin and Non Hodgkin Lymphomas) (Dong et al, 2008). In another study of Johri et al PAX-5 expression was identified in 23/24(95.8%) in hodgkin lymphoma and 32/39 in B cell non hodgkin lymphoma (Johri et al, 2016). In comparison to other studies our study all cases are PAX-5 positive,all Hodgkin lymphoma cases showed moderate(dim) positivity in RS cells and Non-hodgkin lymphomas are strongly positive for PAX-5 and only two cases showed moderate(dim)positivity instead of strong positivity.…”

Section: Resultsmentioning

confidence: 99%

“…For each case, one representative section was selected and immunohistochemical stains were performed. These included Leucocyte common antigen (LCA/CD45), Pan B (CD20, CD79a), Pan T (CD3), CD30 (ki-1), CD15 (GAA), CD 5, CD10, BCL2, cyclin D1 and PAX-5 immunohistochemical stains.For PAX-5, nuclear brown staining of B cell was regarded as positive and it was scored as 0 (weak), 1 (moderate), and 2 (strong) on the basis of intensity of staining (McCuneet al, 2006;Johri et al, 2016). A diagnosis of Hodgkin lymphoma was given for those cases in which typical Reed Sternberg (RS) cells were present in a mixed background comprising of lymphocytes, eosinophils and plasma cells.…”

Section: Data Collectionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma

Khan

Ahmad

Kayani

et al. 2018

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: B-cell malignancies including Precursor B-cell lymphoblastic lymphoma/leukemia and Hodgkin Lymphoma show a wide spectrum of B-cell differentiation from early stage B-cell precursors to mature B-cells ending in terminal differentiation to plasma cells. Pan-B-cell antigens routinely used for the diagnosis of B-cell lymphoma, include CD19, CD20, CD22 and CD79a.PAX-5 protein, also known as B-cell-specific activation protein is a B-cell-specific transcription factor; essential for commitment and functional maintenance used in the diagnosis of B cell Hodgkin and non-Hodgkin lymphoma. PAX-5 show nuclear positivity in B cell lymphomas and moderate (dim) positivity in Hodgkinlymphoma Reed Sternberg cells make this marker ideal for diagnosing B cell malignances. Objective: To determine the expression of PAX-5 in B cell Hodgkin and non-Hodgkin Lymphoma in order to improve the diagnosis of B-cell lymphomas. Methods: In this Prospective study, all the cases of B cell lymphoma diagnosed at The Aga Khan University Hospital, Karachi from July 2010 to July 2011were included. A panel of Immunohistochemical stain was performed in all cases along with additional PAX- 5 stain with appropriate controls. Results: Total 125 cases were included. Hodgkin Lymphoma (Mixed cellularity) was the commonest B-cell lymphoma subtype, 32 (25%) cases. Other common subtypes included Hodgkin lymphoma (Nodular sclerosis subtype), diffuse large B-cell lymphoma and B lymphoblastic lymphoma. Conclusion: This study demonstrates that PAX-5 is the most sensitive and reliable immuhohistochemicalmarker in the diagnosis of B cell Hodgkin and non-Hodgkin lymphoma.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Data Collectionmentioning

confidence: 99%

Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma

Khan

Ahmad

Kayani

et al. 2018

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Johri et al . have identified 1 case out of 24 cases of CHL that lacked expression of PAX5 , whereas Nguyen et al have found 2 cases of PAX5 negative from 74 cases of CHL appraised in their study . In terms of the clinical significance, PAX5 negative staining in CHL is unknown.…”

Section: Transcriptional Signaling In Hodgkin Lymphomamentioning

confidence: 92%

Use of flow cytometry in the phenotypic diagnosis of hodgkin's lymphoma

Grewal

Abayomi

Tomuleasa

et al. 2018

Cytometry Part B Clinical

View full text Add to dashboard Cite

Hodgkin's lymphoma (HL) has a unique immunophenotype derived from immunohistochemistry (positive for CD15, CD30, and Pax‐5; negative for CD3, CD20 in most cases, and CD45). The knowledge gained over recent years enables better diagnosis, prognosis, and treatment of HL. Flow cytometry as a tool for the diagnosis of classic HL has not been useful in the past due to the difficulty in isolating Reed–Sternberg cells as they are admixed in a rich inflammatory background which consists mainly of T cells, B cells, eosinophils, histiocytes, and plasma cells. However, in the recent past, several studies have tried to identify Reed–Sternberg cells using flow cytometry on fine needle aspiration or tissue biopsy of lymph nodes to confirm or supplement immunohistochemistry staining in diagnosis. Newer and more sensitive tools such as flow cytometry can be used for diagnosis, technology that may have been difficult in the past for diagnosis of this lymphoma subtype. Using flow cytometry, diagnosis is faster and could lead to point‐of‐care technology especially where we have typical immunophenotype signatures. © 2018 International Clinical Cytometry Society

show abstract

“…Hertel et al showed 4 cases of PAX5-negative classical Hodgkin lymphoma nodular sclerosis and one case of CHL, mixed cellularity type from 18 cases evaluated in the study [ 5 ]. In another study performed by Johri et al one case out of 24 cases of CHL lacked expression of PAX5 [ 8 ]. A study by Foss et al showed 3 cases of CHL without expression of PAX5 by immunohistochemistry out of 31 cases that were evaluated [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

PAX5-Negative Classical Hodgkin Lymphoma: A Case Report of a Rare Entity and Review of the Literature

Betts

Dwyre

Wang

et al. 2017

Case Reports in Hematology

View full text Add to dashboard Cite

Classical Hodgkin lymphoma (CHL) is recognized as a B-cell neoplasm arising from germinal center or postgerminal center B-cells. The hallmark of CHL is the presence of CD30 (+) Hodgkin and Reed-Sternberg (HRS) cells with dim expression of PAX5. Nearly all of the HRS cells are positive for PAX5. However, a small minority of HRS cells may lack PAX5 expression, which can cause a diagnostic dilemma. Herein we describe two cases of PAX5-negative CHL and review of the English literature on this very rare entity. It is crucial to be aware of this phenomenon, which in some cases may lead to misdiagnosis and may ultimately adversely affect patient's management.

show abstract

Diagnostic Utility of PAX5 in Hodgkin and Non-Hodgkin Lymphoma: A Study from Northern India

Cited by 8 publications

References 15 publications

Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma

Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma

Use of flow cytometry in the phenotypic diagnosis of hodgkin's lymphoma

PAX5-Negative Classical Hodgkin Lymphoma: A Case Report of a Rare Entity and Review of the Literature

Contact Info

Product

Resources

About